Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for 7 and pembrolizumab 200 mg IV on day 1 prior to surgery
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie rak piersi (niedrobnokomórkowy), stadium T1b-T3, N0-N3, M0
- •Kandydat do operacyjnego leczenia radykalnego
- •Dostępna próbka tkanki z biopsji do badań
- •Planowana operacja usunięcia guza i węzłów chłonnych po chemioterapii przedoperacyjnej
- •Rak potrójnie ujemny (brak receptorów estrogenowych, progesteronowych i HER2)
- •Zadowalająca funkcja narządów wewnętrznych (wątroba, nerki, krew)
- •Brak przerzutów odległych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- December 16, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
University of Illinois
Chicago, United States
Trial contact
Oana Danciu, MD
Prathmika Jha, BS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.